Last updated 3 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
GlaxoSmithKline announced on January 7, 2026, that bepirovirsen, an experimental drug for chronic hepatitis B, had succeeded in two massive Phase III trials involving over 1,800 patients across 29 countries. The drug achieved functional cure rates that were statistically significant and “clinically meaningful.” For the 250 million people worldwide living with chronic hepatitis B—most of whom face either lifelong daily medication or progressive liver disease—this represents the first realistic prospect of a six-month treatment that might end their infection rather than suppress it indefinitely.
GSK plans to file for FDA approval in the first quarter of 2026. The drug already has Fast Track designation from the US FDA and Breakthrough Therapy designation in China.
How Bepirovirsen Works
If you have chronic hepatitis B, your doctor prescribes a nucleos(t)ide analogue—drugs like entecavir or tenofovir that suppress viral replication. They prevent cirrhosis, liver cancer, and death. But you take them every day, forever. Stop the pills, and the virus comes roaring back within weeks.
The functional cure rate with these drugs is about one percent.
Bepirovirsen is a synthetic genetic snippet designed to bind to the virus’s RNA and destroy it before it can make more copies. This type of molecule is called an antisense oligonucleotide. It does three things simultaneously: it blocks viral DNA replication by targeting the genetic instructions the virus uses to copy itself; it reduces hepatitis B surface antigen—the viral protein that floods the bloodstream in chronic infection and suppresses the immune system’s ability to fight back; and it activates toll-like receptor 8, which may help the immune system control the infection it’s been ignoring for years.
This triple mechanism—viral suppression plus immune activation—allows the treatment to train your immune system to control the virus on its own, permanently, even after you stop taking the drug.
Phase III Trial Results
The B-Well 1 and B-Well 2 trials were identically designed, double-blind, placebo-controlled studies. Patients were already taking nucleos(t)ide analogues and had baseline hepatitis B surface antigen levels of 3,000 IU/ml or lower. They received either the experimental drug plus their existing medication, or placebo plus their existing medication.
The primary endpoint was functional cure, defined as hepatitis B surface antigen loss and undetectable viral DNA for at least 24 weeks after finishing treatment.
GSK says the trials met this endpoint with statistical significance. The company noted that patients with baseline antigen levels of 1,000 IU/ml or lower did better. If your viral antigen levels are already relatively low, the treatment works better.
The safety profile was “acceptable” and “consistent with Phase II studies.” We won’t know the full safety story until the detailed data comes out.
FDA Expedited Pathways Explained
Breakthrough Therapy designation, which the drug has in China, is granted when preliminary clinical evidence suggests a drug may offer substantial improvement over existing treatments for a serious condition. The benefits include more frequent meetings with FDA reviewers, the ability to submit data in pieces as it becomes available instead of waiting for everything at once (called rolling review), and eligibility for Priority Review.
These expedited pathways don’t officially lower the evidence bar. Regulators still require proof from large, well-designed studies that the drug is safe and works. Critics argue that faster timelines mean less time to identify safety signals, less opportunity for independent review, and more pressure on FDA staff to approve drugs that might not be ready.
This drug’s situation differs in important ways. It’s not using accelerated approval, which allows drugs to market based on a lab measurement that might predict real health benefits but isn’t itself proof of benefit (called surrogate endpoints). The endpoint here—sustained loss of viral antigen and undetectable virus—is a real clinical outcome, not a surrogate marker. The Phase III trials were large, well-designed, and apparently successful.
The trials assessed functional cure at 24 weeks after treatment completion. Complete trial design details, including total follow-up duration, have not been fully disclosed and are expected to be presented at an upcoming scientific congress. What happens at one year? Five years? If 30% of patients achieve functional cure at six months but half of them relapse by year two, that changes the calculus significantly. Regulators could require post-approval studies tracking long-term durability.
Access and Affordability
Chronic hepatitis B is endemic in parts of Africa, Asia, and the Pacific, where screening is limited, vaccination programs are incomplete, and most people with the infection don’t know they have it.
Many of these patients don’t have access to nucleos(t)ide analogues, which have been around for decades and are relatively cheap. They’re certainly not going to have access to this new treatment at launch.
Antisense oligonucleotides are expensive to manufacture. They require specialized chemistry, quality control, and often cold-chain distribution. Drugs in this class have historically been priced in the tens or hundreds of thousands of dollars per treatment course. GSK hasn’t announced pricing.
A functional cure for hepatitis B might be available in London and Los Angeles but not in Lagos or Laos, precisely the places where the disease burden is highest. Tiered pricing, voluntary licensing agreements, and generic manufacturing partnerships could address this—but they require deliberate policy choices that pharmaceutical companies don’t make unless pressured.
What “Functional Cure” Means
Functional cure is not the same as eradication. The virus doesn’t disappear completely. Small amounts of viral DNA remain integrated into liver cell genomes, potentially for life. But in a functional cure, the immune system keeps the virus suppressed without medication. Hepatitis B surface antigen stays undetectable. Viral DNA stays undetectable. Liver inflammation resolves. The risk of cirrhosis and cancer drops substantially.
For patients, this matters because of what chronic infection does to your life. You can’t donate blood. You worry about transmitting the virus to sexual partners or family members. You face discrimination in employment and insurance in countries without strong legal protections. You live with the knowledge that your liver might fail in 20 years despite doing everything right.
Functional cure changes that calculation. You’re still monitoring liver function and getting screened for cancer, but you’re not sick anymore and you’re not taking drugs.
Other Functional Cure Candidates in Development
Bepirovirsen is not the only functional cure candidate in development. Other companies are also working on functional cure approaches.
First-mover advantage in pharmaceuticals isn’t as durable as in tech. If this drug launches in 2027 but a competitor launches in 2028 with better efficacy, fewer side effects, or more convenient dosing, GSK’s market position erodes quickly.
For patients, competition drives prices down, encourages innovation, and creates options for people who don’t respond to or can’t tolerate the first drug.
Critical Questions for Regulators
How durable is functional cure beyond 24 weeks? The trials proved sustained response for six months post-treatment. But hepatitis B is a lifelong infection. If 40% of “cured” patients relapse at 18 months, you haven’t cured them—you’ve given them a drug holiday. The agency should require at least three-year follow-up data, ideally five.
What happens in patients with higher baseline antigen levels? The trials capped enrollment at 3,000 IU/ml and showed better results below 1,000 IU/ml. Many real-world patients have antigen levels above 3,000. Do they get no benefit? Worse outcomes? More side effects? The label needs to address this clearly.
Does the drug work without background nucleos(t)ide analogue therapy? All trial participants were already on standard treatment. That’s scientifically reasonable—you want to isolate the drug’s effect—but it means we don’t know if it works as monotherapy. If it doesn’t, that limits its utility in resource-poor settings where nucleos(t)ide analogues aren’t consistently available.
What about resistance mutations? Some patients harbor virus strains that have learned to survive the current medications (called nucleos(t)ide analogue resistance). The mechanism of this drug—targeting viral RNA rather than the enzyme hepatitis B uses to copy its genetic material (reverse transcriptase)—suggests it might work in these patients, but the trials probably didn’t include enough of them to know for sure.
What about hepatitis D co-infection? Hepatitis D is a virus that can only survive if hepatitis B is also present, and co-infected patients have worse outcomes. They’re a meaningful subset in certain regions. If the drug doesn’t work in co-infection, or hasn’t been tested, that’s a significant limitation.
Regulators have authority to require post-approval studies addressing these questions. Whether they’ll use that authority aggressively, and whether they’ll enforce compliance if GSK drags its feet on conducting those studies, is an open question with a mixed track record.
Implications for FDA Reform and Drug Approval
The approval pathway for this drug will be cited for years in debates about FDA reform, drug pricing, and global health equity. It’s a test case for whether expedited review can deliver transformative drugs without cutting corners on safety.
If the drug works as advertised, maintains durable functional cure rates in real-world use, and doesn’t develop unexpected safety signals in broader populations, it validates the Breakthrough Therapy model. If the drug gets approved, launches at a high price, shows declining efficacy in long-term follow-up, or develops safety problems that weren’t apparent in 1,800-patient trials, it becomes ammunition for critics who argue the agency is too cozy with industry and too willing to approve drugs on insufficient evidence.
This treatment will help some patients significantly, help others modestly, and not work at all for a subset who needed it most. The question is whether the regulatory process accurately characterized those probabilities before approval, and whether the price and access policies ensure the people who can benefit get the drug.
Historical Precedent: Hepatitis C
The pharmaceutical industry has a history of developing transformative treatments that remain out of reach for the populations that need them most. Hepatitis C provides a recent example: direct-acting antivirals achieved cure rates above 95%, yet millions of people in low- and middle-income countries still can’t access them a decade after approval. The same pattern could repeat with hepatitis B unless policymakers, advocacy groups, and international health organizations negotiate access agreements before launch rather than after.
GSK will file its application in the coming weeks. Regulators will review it over the next six to nine months. Patient advocacy groups will push for rapid approval. Some scientists will urge caution. And 250 million people with chronic hepatitis B will wait to see if this changes anything for them, or if it’s another expensive drug they’ll never be able to access.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.